About Us
Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
The company is led by a seasoned management team and is supported by a network of world-leading experts in the field of ADC development.
Adcytherix is backed by a syndicate of leading life science investors including Pontifax, Pureos Bioventures, RA Capital Management and Dawn Biopharma (a platform controlled by KKR).
Adcytherix is based in Marseille, France.
Management Team
Jack Elands
CEO and company founder
Dr. Jack Elands is founder and former CEO of Emergence Therapeutics, Talix Therapeutics, CEO of BliNK Biomedical and CEO and co-founder of Amakem, CEO of Vitec, co-founder of MImAbs
Carsten Dehning
CFO and co-founder
Carsten Dehning is former CFO and co-founder of Emergence Therapeutics, former CFO, CEO and senior advisor of various companies and investors in the healthcare sector
Xavier Preville
VP, Head of Research & Pre-Clinical Development and co-founder
Dr. Xavier Preville is co-founder and former CSO of Emergence Therapeutics, former CSO at Talix Therapeutics, director of preclinical development at Transgene and BT Pharma (Genticel)
Thierry Menguy
Senior Director, Head of CMC operations
Dr. Thierry Menguy is the former head of CMC at LinKinVax, CTO and co-founder at ElsaLys Biotech. He has also held senior positions in CMC and R&D of large molecules at Transgene, Biométhodes and Genodyssee
Supervisory Committee
Ran Nussbaum
Managing Partner at Pontifax Venture Capital
Ohad Hammer
Partner at Pontifax Venture Capital
Ximing Ding
Investment Manager at Pureos Bioventures
Iyona Rajkomar
Managing Partner at Dawn Biopharma (a platform controlled by KKR)
Matthew Hammond
Principal at RA Capital Management